A Phase 2 interventional study of Standard taxane therapy and capecitabine [Xeloda] in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 13 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-29.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.
Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 161st largest by enrollment of the 227 interventional ones that give a count, is one of 12 that started in 2009, is one of 121 in phase 2, and was the 104th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Biostar Pharma, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
233 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 146 · Phase 3 55 · Phase 4 6
First in 1998; this study’s year is marked. 12 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 54 across the 227 interventional studies. Of the 149 that completed or were terminated, 54 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 233 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 147th largest by enrollment of the 170 interventional ones that give a count, is one of 18 that started in 2009, is one of 65 in phase 2, and was the 49th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
8 of the studies testing capecitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04768426Stanford UniversitySerial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | 2026-11 |
| NCT06016387Sunnybrook Health Sciences CentreTucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | 2026-12-31 |
| NCT06764940Biostar Pharma, Inc.A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | 2027-01-15 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
| NCT06247995Novartis PharmaceuticalsA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | 2027-04-14 |
Add all 8 to your calendar (.ics) → With an account.
Among the 233 studies testing capecitabine in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single arm study will evaluate alterations in molecular marker expression in HER2-positive targeted therapy, and will evaluate the effect of continued treatment with Herceptin and Xeloda beyond progression following initial Herceptin-taxane chemotherapy. Patients who develop progressive disease will receive first-line Herceptin (8mg/kg iv loading dose and 6mg/kg iv every 3 weeks) + taxane therapy. patients who develop progressive disease within 9 weeks of treatment will continue treatment with Herceptin in combination with Xeloda (1000mg/m2 po bid on days 1-14 of each 3-week cycle).Biopsies of tumor tissue will be taken for biomarker and gene profiling evaluation. The anticipated time on study treatment is until disease progression, intolerable side effects or patient choice, and the target sample size is 100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Standard taxane therapy · Drug: capecitabine [Xeloda] · Drug: trastuzumab [Herceptin]
As prescribed
1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
Part I: Progression Free Survival (PFS) by Biomarker
Progression was defined as an increase by at least 20 percent (%) from the smallest value in the Sum of Longest Diameter (SLD) of lesions. Biomarkers investigated: p95 human epidermal growth factor receptor 2 (p95HER2) positive (+ve) and negative (-ve) , insulin growth factor-1 receptor (IGF1R) less than (\<) median and greater than or equal to (≥) median membrane H score, c-MET \<median and ≥median membrane H score, phosphatase and tensin homolog gene (PTEN) \<median and ≥median cytoplasm H score, HER2 \<median and ≥median membrane H score, phosphatidylinositol-3-kinase (PI3K) catalytic subunit wild type (WT) and mutation (M), and FC gamma receptors IIIa homozygous Phenyl alanine (FF), heterozygous Phenyl alanine/Valine (VF) and homozygous Valine (VV), receptor IIa Phenotypes homozygous Histidine (HH), heterozygous Histidine/Arginine (HR) and homozygous Arginine (RR) IIb phenotypes homozygous Isoleucien (II),heterozygous Isoleucine/Threonine (IT) and homozygous Threonine (TT) .
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Part II: Progression Free Survival (PFS) by Biomarker
PFS was calculated from first study medication in Part II to date of progression or death.The relationship between PFS and the following biomarker variables was investigated in each of study Part 1 and 2: p95HER2 +ve and -ve population, IGF1R \<median and ≥ median membrane H score, c-MET \<median and ≥median membrane H score, PTEN \<median and ≥median cytoplasm H score, HER2 \<median and ≥median membrane H score, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Part I: Time to Progression (TTP) by Biomarker
Progression was defined as an increase by at least 20% from the smallest value in the SLD of lesions.TTP was determined as the time in months from the date of screening until first progression.The relationship between PFS and the following biomarker variables was investigated in each of study Part 1 and 2: p95 HER2 +ve and -ve population, IGF1R \<median and ≥median, c-MET \<median and ≥median, PTEN \<median and ≥median, HER2 \<median and ≥median, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT . The correlation between the biomarker variables and TTP were investigated using a univariate Cox regression model and time-to-event methods (Kaplan-Meier).
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 weeks
Part II: TTP by Biomarker
TTP was calculated from first study medication in Part II to date of progression. The relationship between TTP and the following biomarker variables was investigated in each of study Part 1 and 2: p95 HER2 +ve and -ve population, IGF1R \<median and ≥median, c-MET \<median and ≥median, PTEN \<median and ≥median, HER2 \<median and ≥median, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT .
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Part I: Percentage of Participants With a Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progrerssive Disease (PD) by Biomarker
BOR was defined according to the Response Evaluation Criteria In Solid Tumors (RECIST). CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions. The relationship between best response and the following biomarkers was investigated: p95 HER2 (+ve/-ve), IGF1R, c-MET, PTEN, HER2 (median/≥median), PI3K catalytic subunit (WT/M), and FC gamma receptors IIIa, IIa and IIb (phenotypes FF, VF, VV, HH, HR, RR and II, IT and TT respectively). The correlation between the biomarker variables and percentage of participants with best response were investigated using a univariate regression analysis.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 weeks
Part II: Percentage of Participants With a Best Overall Response of CR, PR, SD or PD by Biomarker
Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm.PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions. The relationship between best response and the following biomarkers was investigated: p95 HER2 (+ve/-ve), IGF1R, c-MET, PTEN, HER2 (\<median/≥median) , PI3K catalytic subunit (WT/M), and FC gamma receptors IIIa, IIa and IIb (phenotypes FF, VF, VV, HH, HR, RR and II, IT and TT respectively). The correlation between the biomarker variables and percentage of participants with best response were investigated using a univariate regression analysis.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Part I: TTP in Intent to Treat (ITT) Population
TTP was determined as the time in months from the date of screening until first progression. In participants with measurable disease, progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Part I: PFS in ITT Population
PFS was determined as the time in months from the date of screening until first progression. In participants with measurable disease, progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]).. In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Part II: TTP in Intent to Treat (ITT) Population
TTP was calculated from first study medication in Part II to date of progression. In participants with measurable disease progression was defined according to RECIST(SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Part II: PFS in ITT Population
PFS was calculated from first study medication in Part II to date of progression or death. In participants with measurable disease progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Overall Survival in Per Protocol Population
Overall survival was calculated in months from the day of screening until death.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until death (up to 46 months)
Overall Survival in ITT Population
Overall survival was calculated in months from the day of screening until death.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until death (up to 46 months)
Part I and II: Percentage of Participants With a Best Overall Response of CR or PR in ITT Population
Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 Cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
Part I and II: Percentage of Participants With a Response by Best Overall Response by CR, PR, SD or PD in ITT Population
Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions.
Time frame: End of first 2 Cycles (Weeks 3 and 6), every 3 cycles for 18 weeks, then every 4 cycles until progression, unacceptable toxicity or participant decision to cease treatment up to 46 months
| Milestone | Group A:Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks | No Group |
|---|---|---|---|
| Started | 31 | 1 | 1 |
| Completed | 13 | 1 | 0 |
| Not completed | 18 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Unknown reason | 16 | 0 | 0 |
| Withdrew: Sufficient response achieved | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 |
| Milestone | Group A:Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks | No Group |
|---|---|---|---|
| Started | 13 | 1 | 0 |
| Completed | 8 | 1 | 0 |
| Not completed | 5 | 0 | 0 |
| Withdrew: Unknown reason | 5 | 0 | 0 |
Progression was defined as an increase by at least 20 percent (%) from the smallest value in the Sum of Longest Diameter (SLD) of lesions. Biomarkers investigated: p95 human epidermal growth factor receptor 2 (p95HER2) positive (+ve) and negative (-ve) , insulin growth factor-1 receptor (IGF1R) less than (\<) median and greater than or equal to (≥) median membrane H score, c-MET \<median and ≥median membrane H score, phosphatase and tensin homolog gene (PTEN) \<median and ≥median cytoplasm H score, HER2 \<median and ≥median membrane H score, phosphatidylinositol-3-kinase (PI3K) catalytic subunit wild type (WT) and mutation (M), and FC gamma receptors IIIa homozygous Phenyl alanine (FF), heterozygous Phenyl alanine/Valine (VF) and homozygous Valine (VV), receptor IIa Phenotypes homozygous Histidine (HH), heterozygous Histidine/Arginine (HR) and homozygous Arginine (RR) IIb phenotypes homozygous Isoleucien (II),heterozygous Isoleucine/Threonine (IT) and homozygous Threonine (TT) .
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks |
|---|---|---|
| p95 HER2 +ve (n=9,0) | NA (3.384 to NA) | NA (NA to NA) |
| p95 HER2 -ve (n=15,1) | 13.963 (7.261 to 22.407) | 1.216 (NA to NA) |
| IGF1R <median (n=12,0) | 12.649 (4.698 to NA) | NA (NA to NA) |
| IGF1R ≥median (n=14,1) | 22.209 (7.261 to NA) | 1.216 (NA to NA) |
| c-MET <median (n=10,1) | 18.595 (3.384 to NA) | 1.216 (NA to NA) |
| c-MET ≥median (n=15,0) | 13.733 (7.031 to NA) | NA (NA to NA) |
| PTEN <median (n=12,0) | 22.209 (5.914 to NA) | NA (NA to NA) |
| PTEN ≥median (n=14,1) | 13.963 (6.374 to 31.179) | 1.216 (NA to NA) |
| HER2 <median (n=11,1) | 13.733 (3.384 to NA) | 1.216 (NA to NA) |
| HER2 ≥median (n=14,0) | 22.209 (7.031 to NA) | NA (NA to NA) |
| PI3K Amino Acids WT (n=17,1) | 13.848 (7.261 to NA) | 1.216 (NA to NA) |
| PI3K Amino Acids M (n=9,0) | 22.407 (4.698 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIIa F176V FF (n=9,0) | 10.612 (3.384 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIIa F176V VF (n=5,1) | 11.335 (9.528 to NA) | 1.216 (NA to NA) |
| FC Gamma Receptor IIIa F176V VV (n=4,0) | 22.407 (22.209 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIa R166H HH (n=3,0) | NA (9.528 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIa R166H HR (n=8,1) | 22.209 (3.384 to NA) | 1.216 (NA to NA) |
| FC Gamma Receptor IIa R166H RR (n=8,0) | 13.963 (5.914 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIb I232T II (n=12,1) | 11.335 (5.914 to NA) | 1.216 (NA to NA) |
| FC Gamma Receptor IIb I232T IT (n=1,0) | NA (NA to NA) | NA (NA to NA) |
| FC Gamma Receptor IIb I232T TT (n=1,0) | NA (NA to NA) | NA (NA to NA) |
TTP was determined as the time in months from the date of screening until first progression. In participants with measurable disease, progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks |
|---|---|---|
| Part I: TTP in Intent to Treat (ITT) Population | 22.21 (9.53 to NA) | 1.22 (NA to NA) |
PFS was calculated from first study medication in Part II to date of progression or death.The relationship between PFS and the following biomarker variables was investigated in each of study Part 1 and 2: p95HER2 +ve and -ve population, IGF1R \<median and ≥ median membrane H score, c-MET \<median and ≥median membrane H score, PTEN \<median and ≥median cytoplasm H score, HER2 \<median and ≥median membrane H score, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT.
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks |
|---|---|---|
| p95 +ve (n=2,0) | 8.148 (NA to NA) | NA (NA to NA) |
| p95 -ve (n=5,1) | 3.450 (0.854 to 8.115) | 13.832 (NA to NA) |
| IGF1R <median (n=4,0) | 8.115 (0.854 to 8.115) | NA (NA to NA) |
| IGF1R ≥median (n=4,1) | 4.074 (1.971 to 8.148) | 13.832 (NA to NA) |
| c-MET<median (n=3,1) | 4.698 (3.450 to 4.698) | 13.832 (NA to NA) |
| c-MET≥median (n=4,0) | 5.043 (0.854 to 8.148) | NA (NA to NA) |
| PTEN <median (n=4,0) | 4.698 (1.971 to 8.115) | NA (NA to NA) |
| PTEN ≥median (n=3,1) | 3.450 (0.854 to 8.148) | 13.832 (NA to NA) |
| HER2 <median (n=2,1) | 8.148 (NA to NA) | 13.832 (NA to NA) |
| HER2 ≥median (n=5,0) | 3.450 (0.854 to 8.115) | NA (NA to NA) |
| PI3K Amino Acids WT (n=10,1) | 5.651 (1.971 to 24.214) | 13.832 (NA to NA) |
| PI3K Amino Acids M (n=2,0) | 4.485 (0.854 to 8.115) | NA (NA to NA) |
| FC Gamma Receptor IIIa F176V FF (n=4,0) | 4.320 (0.854 to 8.148) | NA (NA to NA) |
| FC Gamma Receptor IIIa F176V VF (n=2,1) | 13.832 (3.450 to 24.214) | 13.832 (NA to NA) |
| FC Gamma Receptor IIIa F176V VV (n=2,0) | NA (NA to NA) | NA (NA to NA) |
| FC Gamma Receptor IIa R166H HH (n=1,0) | 3.450 (NA to NA) | NA (NA to NA) |
| FC Gamma Receptor IIa R166H HR (n=5,1) | 8.115 (0.854 to 8.148) | 13.832 (NA to NA) |
| FC Gamma Receptor IIa R166H RR (n=3,0) | 5.651 (2.990 to 24.214) | NA (NA to NA) |
| FC Gamma Receptor IIb I232T II (n=7,1) | 5.651 (0.854 to 24.214) | 13.832 (NA to NA) |
Progression was defined as an increase by at least 20% from the smallest value in the SLD of lesions.TTP was determined as the time in months from the date of screening until first progression.The relationship between PFS and the following biomarker variables was investigated in each of study Part 1 and 2: p95 HER2 +ve and -ve population, IGF1R \<median and ≥median, c-MET \<median and ≥median, PTEN \<median and ≥median, HER2 \<median and ≥median, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT . The correlation between the biomarker variables and TTP were investigated using a univariate Cox regression model and time-to-event methods (Kaplan-Meier).
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks |
|---|---|---|
| p95 +ve (n=9,0) | NA (3.384 to NA) | NA (NA to NA) |
| p95 -ve (n=15,1) | 13.963 (7.261 to 22.407) | 1.216 (NA to NA) |
| IGF1R <median (n=12,0) | 11.335 (4.698 to NA) | NA (NA to NA) |
| IGF1R ≥median (n=14,1) | 22.407 (5.914 to NA) | 1.216 (NA to NA) |
| c-MET <median (n=10,1) | 31.179 (3.384 to NA) | 1.216 (NA to NA) |
| c-MET ≥median (n=15,0) | 22.209 (6.374 to NA) | NA (NA to NA) |
| PTEN <median (n=12,0) | 22.209 (5.914 to NA) | NA (NA to NA) |
| PTEN ≥median (n=14,1) | 13.963 (6.374 to 31.179) | 1.216 (NA to NA) |
| HER2 <median (n=11,1) | NA (3.384 to NA) | 1.216 (NA to NA) |
| HER2 ≥median (n=14,0) | 22.209 (7.031 to NA) | NA (NA to NA) |
| PI3K Amino Acids WT (n=17,1) | 13.963 (7.261 to NA) | 1.216 (NA to NA) |
| PI3K Amino Acids M (n=9,00) | 22.407 (4.698 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIIa F176V FF (n=9,0) | 13.963 (3.384 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIIa F176V VF (n=5,1) | 11.335 (9.528 to NA) | 1.216 (NA to NA) |
| FC Gamma Receptor IIIa F176V VV (n=4,0) | 22.407 (22.209 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIa R166H HH (n=3,0) | NA (9.528 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIa R166H HR (n=8,1) | 22.209 (3.384 to NA) | 1.216 (NA to NA) |
| FC Gamma Receptor IIa R166H RR (n=8,0) | 13.963 (5.914 to NA) | NA (NA to NA) |
| FC Gamma Receptor IIb I232T II (n=12,1) | 13.963 (5.914 to NA) | 1.216 (NA to NA) |
| FC Gamma Receptor IIb I232T IT (n=1,0) | NA (NA to NA) | NA (NA to NA) |
| FC Gamma Receptor IIb I232T TT (n=1,0) | NA (NA to NA) | NA (NA to NA) |
PFS was determined as the time in months from the date of screening until first progression. In participants with measurable disease, progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]).. In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks |
|---|---|---|
| Part I: PFS in ITT Population | 18.60 (8.08 to NA) | 1.22 (NA to NA) |
TTP was calculated from first study medication in Part II to date of progression. In participants with measurable disease progression was defined according to RECIST(SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks |
|---|---|---|
| Part II: TTP in Intent to Treat (ITT) Population | 5.65 (2.99 to 8.15) | 13.83 (NA to NA) |
PFS was calculated from first study medication in Part II to date of progression or death. In participants with measurable disease progression was defined according to RECIST (SLD increased by at least 20% from the smallest value on study \[including baseline, if that is the smallest\]). In participants with non-measurable disease, progression was defined as the presence of new lesions or unequivocal progression during treatment.
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks |
|---|---|---|
| Part II: PFS in ITT Population | 5.65 (2.99 to 24.21) | 13.83 (NA to NA) |
Overall survival was calculated in months from the day of screening until death.
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) |
|---|---|
| Overall Survival in Per Protocol Population | 36.40 (6.57 to 40.28) |
Overall survival was calculated in months from the day of screening until death.
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) |
|---|---|
| Overall Survival in ITT Population | NA (6.57 to 40.28) |
Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions.
| percentage of participants | Group A: Trastuzumab+Taxane /Capcetabine (6 Weeks) |
|---|---|
| Part I: Responders (n=20) | 75.0 |
| Part I: Non-Responders (n=20) | 20.0 |
| Part I: Missing (n=20) | 5.0 |
| Part II: Responders (n=9) | 11.1 |
| Part II: Non-Responders (n=9) | 88.9 |
| Part II: Missing (n=9) | 0.0 |
TTP was calculated from first study medication in Part II to date of progression. The relationship between TTP and the following biomarker variables was investigated in each of study Part 1 and 2: p95 HER2 +ve and -ve population, IGF1R \<median and ≥median, c-MET \<median and ≥median, PTEN \<median and ≥median, HER2 \<median and ≥median, PI3K catalytic subunit WT and M, and FC gamma receptors IIIa, IIa and IIb Phenotypes FF, VF and VV, HH, HR and RR, and II, IT and TT .
| months | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks |
|---|---|---|
| p95 HER2 +ve (n=2,0) | 8.148 (NA to NA) | NA (NA to NA) |
| p95 HER2 -ve (n=5,1) | 3.450 (0.854 to 8.115) | 13.832 (NA to NA) |
| IGF1R <median (n=4,0) | 8.115 (0.854 to 8.115) | NA (NA to NA) |
| IGF1R ≥median (n=4,1) | 4.074 (1.971 to 8.148) | 13.832 (NA to NA) |
| c-MET <median (n=3,1) | 4.698 (3.450 to 4.698) | 13.832 (NA to NA) |
| c-MET ≥median (n=4,0) | 5.043 (0.854 to 8.148) | NA (NA to NA) |
| PTEN <median (n=4,0) | 4.698 (1.971 to 8.115) | NA (NA to NA) |
| PTEN ≥median (n=3,1) | 3.450 (0.854 to 8.148) | 13.832 (NA to NA) |
| HER2 <median (n=2,1) | 8.148 (NA to NA) | 13.832 (NA to NA) |
| HER2 ≥median (n=5,0) | 3.450 (0.854 to 8.115) | NA (NA to NA) |
| PI3K Amino Acids WT (n=10,1) | 5.651 (1.971 to 8.148) | 13.832 (NA to NA) |
| PI3K Amino Acids M (n=2,0) | 4.485 (0.854 to 8.115) | NA (NA to NA) |
| FC Gamma Receptor IIIa F176V FF (n=4,0) | 4.320 (0.854 to 8.148) | NA (NA to NA) |
| FC Gamma Receptor IIIa F176V VF (n=2,1) | NA (3.450 to NA) | 13.832 (NA to NA) |
| FC Gamma Receptor IIIa F176V VV (n=2,0) | NA (NA to NA) | NA (NA to NA) |
| FC Gamma Receptor IIa R166H HH (n=1,0) | 3.450 (NA to NA) | NA (NA to NA) |
| FC Gamma Receptor IIa R166H HR (n=5,1) | 8.115 (0.854 to 8.148) | 13.832 (NA to NA) |
| FC Gamma Receptor IIa R166H RR (n=3,0) | 5.651 (2.990 to 5.651) | NA (NA to NA) |
| FC Gamma Receptor IIb I232T II (n=7,1) | 5.651 (0.854 to 8.115) | 13.832 (NA to NA) |
BOR was defined according to the Response Evaluation Criteria In Solid Tumors (RECIST). CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions. The relationship between best response and the following biomarkers was investigated: p95 HER2 (+ve/-ve), IGF1R, c-MET, PTEN, HER2 (median/≥median), PI3K catalytic subunit (WT/M), and FC gamma receptors IIIa, IIa and IIb (phenotypes FF, VF, VV, HH, HR, RR and II, IT and TT respectively). The correlation between the biomarker variables and percentage of participants with best response were investigated using a univariate regression analysis.
| percentage of participants | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) |
|---|---|
| p95 HER2 +ve CR (n=5) | 0.0 |
| p95 HER2 +ve PR (n=5) | 25.0 |
| p95 HER2 +ve SD (n=5) | 50.0 |
| p95 HER2 +ve PD (n=5) | 25.0 |
| p95 HER2 -ve CR (n=12) | 0.0 |
| p95 HER2 -ve PR (n=12) | 91.7 |
| p95 HER2 -ve SD (n=12) | 8.3 |
| p95 HER2 -ve PD (n=12) | 0.0 |
| IGF1R < median CR (n=9) | 0.0 |
| IGF1R < median PR (n=9) | 62.5 |
| IGF1R < median SD (n=9) | 37.5 |
| IGF1R < median PD (n=9) | 0.0 |
| IGF1R ≥median CR (n=9) | 0.0 |
| IGF1R ≥median PR (n=9,0) | 88.9 |
| IGF1R ≥median SD (n=9) | 0.0 |
| IGF1R ≥median PD (n=9) | 11.1 |
| c-MET <median CR (n=6) | 0.0 |
| c-METt <median PR (n=6) | 83.3 |
| c-MET <median SD (n=6) | 0.0 |
| c-MET <median PD (n=6) | 16.7 |
| c-MET ≥median CR (n=11) | 0.0 |
| c-MET ≥median PR (n=11) | 70.0 |
| c-MET ≥median SD (n=11) | 30.0 |
| c-MET ≥median PD (n=11) | 0.0 |
| PTEN <median CR (n=6) | 0.0 |
| PTEN <median PR (n=6) | 83.3 |
| PTEN <median SD (n=6) | 16.7 |
| PTEN <median PD (n=6) | 0.0 |
| PTEN ≥median CR (n=12) | 0.0 |
| PTEN ≥median PR (n=12) | 72.7 |
| PTEN ≥median SD (n=12) | 18.2 |
| PTEN ≥median PD (n=12) | 9.1 |
| HER2 <median CR (n=8) | 0.0 |
| HER2 <median PR (n=8) | 75.0 |
| HER2 <median SD (n=8) | 12.5 |
| HER2 <median PD (n=8) | 12.5 |
| HER2 ≥median CR (n=10) | 0.0 |
| HER2 ≥median PR (n=10) | 77.8 |
| HER2 ≥median SD (n=10) | 22.2 |
| HER2 ≥median PD (n=10) | 0.0 |
| PI3K Amino Acids WT CR (n=11) | 0.0 |
| PI3K Amino Acids WT PR (n=11,0) | 90.0 |
| PI3K Amino Acids WT SD (n=11) | 0.0 |
| PI3K Amino Acids WT PD (n=11) | 10.0 |
| PI3K Amino Acids M CR (n=7) | 0.0 |
| PI3K Amino Acids M PR (n=7,0) | 57.1 |
| PI3K Amino Acids M SD (n=7) | 42.9 |
| PI3K Amino Acids M PD (n=7) | 0.0 |
| FC Gamma Receptor IIIa F176V FF CR (n=6) | 16.7 |
| FC Gamma Receptor IIIa F176V FF PR (n=6) | 50.0 |
| FC Gamma Receptor IIIa F176V FF SD (n=6) | 16.7 |
| FC Gamma Receptor IIIa F176V FF PD (n=6) | 16.7 |
| FC Gamma Receptor IIIa F176V VF CR (n=4) | 0.0 |
| FC Gamma Receptor IIIa F176V VF PR (n=4) | 66.7 |
| FC Gamma Receptor IIIa F176V VF SD (n=4) | 33.3 |
| FC Gamma Receptor IIIa F176V VF PD (n=4) | 0.0 |
| FC Gamma Receptor IIIa F176V VV CR (n=2) | 0.0 |
| FC Gamma Receptor IIIa F176V VV PR (n=2) | 100.0 |
| FC Gamma Receptor IIIa F176V VV SD (n=2) | 0.0 |
| FC Gamma Receptor IIIa F176V VV PD (n=2) | 0.0 |
| FC Gamma Receptor IIa R166H HH CR (n=3) | 33.3 |
| FC Gamma Receptor IIa R166H HH PR (n=3) | 66.7 |
| FC Gamma Receptor IIa R166H HH SD (n=3) | 0.0 |
| FC Gamma Receptor IIa R166H HH PD (n=3) | 0.0 |
| FC Gamma Receptor IIa R166H HR CR (n=5) | 0.0 |
| FC Gamma Receptor IIa R166H HR PR (n=5) | 25.0 |
| FC Gamma Receptor IIa R166H HR SD (n=5) | 50.0 |
| FC Gamma Receptor IIa R166H HR PD (n=5) | 25.0 |
| FC Gamma Receptor IIa R166H RR CR (n=5) | 0.0 |
| FC Gamma Receptor IIa R166H RR PR (n=5) | 80.0 |
| FC Gamma Receptor IIa R166H SD RR (n=5) | 20.0 |
| FC Gamma Receptor IIa R166H RR PD (n=5) | 0.0 |
| FC Gamma Receptor IIb I232T II CR (n=8) | 12.5 |
| FC Gamma Receptor IIb I232T II PR (n=8) | 50.0 |
| FC Gamma Receptor IIb I232T II SD (n=8) | 37.5 |
| FC Gamma Receptor IIb I232T II PD (n=8) | 0.0 |
| FC Gamma Receptor IIb I232T IT CR (n=1) | 0.0 |
| FC Gamma Receptor IIb I232T IT PR (n=1) | 100.0 |
| FC Gamma Receptor IIb I232T IT SD (n=1) | 0.0 |
| FC Gamma Receptor IIb I232T IT PD (n=1) | 0.0 |
Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm.PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions. The relationship between best response and the following biomarkers was investigated: p95 HER2 (+ve/-ve), IGF1R, c-MET, PTEN, HER2 (\<median/≥median) , PI3K catalytic subunit (WT/M), and FC gamma receptors IIIa, IIa and IIb (phenotypes FF, VF, VV, HH, HR, RR and II, IT and TT respectively). The correlation between the biomarker variables and percentage of participants with best response were investigated using a univariate regression analysis.
| percentage of participants | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) |
|---|---|
| p95 HER2 +ve CR (n=2) | 0.0 |
| p95 HER2 +ve PR (n=2) | 0.0 |
| p95 HER2 +ve SD (n=2) | 100.0 |
| p95 HER2 +ve PD (n=2) | 0.0 |
| p95 HER2 -ve CR (n=4) | 0.0 |
| p95 HER2 -ve PR (n=4) | 0.0 |
| p95 HER2 -ve SD (n=4) | 50.0 |
| p95 HER2 -ve PD (n=4) | 50.0 |
| IGF1R <median CR (n=3) | 0.0 |
| IGF1R <median PR (n=3) | 0.0 |
| IGF1R <median SD (n=3) | 66.7 |
| IGF1R <median PD (n=3) | 33.3 |
| IGF1R ≥median CR (n=3) | 0.0 |
| IGF1R ≥median PR (n=3) | 0.0 |
| IGF1R ≥median SD (n=3) | 66.7 |
| IGF1R ≥median PD (n=3) | 33.3 |
| c-MET <median CR (n=2) | 0.0 |
| c-MET <median PR (n=2) | 0.0 |
| c-MET <median SD (n=2) | 100.0 |
| c-MET <median PD (n=2) | 0.0 |
| c-MET ≥median CR (n=4) | 0.0 |
| c-MET ≥median PR (n=4) | 0.0 |
| c-MET ≥median SD (n=4) | 50.0 |
| c-MET ≥median PD (n=4) | 50.0 |
| PTEN <median CR (n=4) | 0.0 |
| PTEN <median PR (n=4) | 0.0 |
| PTEN <median SD (n=4) | 75.0 |
| PTEN <median PD (n=4) | 25.0 |
| PTEN ≥median CR (n=2) | 0.0 |
| PTEN ≥median PR (n=2) | 0.0 |
| PTEN ≥median SD (n=2) | 50.0 |
| PTEN ≥median PD (n=2) | 50.0 |
| HER2 <median CR (n=2) | 0.0 |
| HER2 <median PR (n=2) | 0.0 |
| HER2 <median SD (n=2) | 100.0 |
| HER2 <median PD (n=2) | 0.0 |
| HER2 ≥median CR (n=4) | 0.0 |
| HER2 ≥median PR (n=4) | 0.0 |
| HER2 ≥median SD (n=4) | 50.0 |
| HER2 ≥median PD (n=4) | 50.0 |
| PI3K Amino Acids WT CR (n=7) | 0.0 |
| PI3K Amino Acids WT PR (n=7) | 14.3 |
| PI3K Amino Acids WT SD (n=7) | 71.4 |
| PI3K Amino Acids WT PD (n=7) | 14.3 |
| PI3K Amino Acids M CR (n=2) | 0.0 |
| PI3K Amino Acids M PR (n=2) | 0.0 |
| PI3K Amino Acids M SD (n=2) | 50.0 |
| PI3K Amino Acids M PD (n=2) | 50.0 |
| FC Gamma Receptor IIIa F176V FF CR (n=3) | 0.0 |
| FC Gamma Receptor IIIa F176V FF PR (n=3) | 0.0 |
| FC Gamma Receptor IIIa F176V FF SD (n=3) | 66.7 |
| FC Gamma Receptor IIIa F176V FF PD (n=3) | 33.3 |
| FC Gamma Receptor IIIa F176V VF CR (n=1) | 0.0 |
| FC Gamma Receptor IIIa F176V VF PR (n=1) | 0.0 |
| FC Gamma Receptor IIIa F176V VF SD (n=1) | 100.0 |
| FC Gamma Receptor IIIa F176V VF PD (n=1) | 0.0 |
| FC Gamma Receptor IIIa F176V VV CR (n=1) | 0.0 |
| FC Gamma Receptor IIIa F176V VV PR (n=1) | 100.0 |
| FC Gamma Receptor IIIa F176V VV SD (n=1) | 0.0 |
| FC Gamma Receptor IIIa F176V VV PD (n=1) | 0.0 |
| FC Gamma Receptor IIa R166H HH CR (n=0) | NA |
| FC Gamma Receptor IIa R166H HH PR (n=0) | NA |
| FC Gamma Receptor IIa R166H HH SD (n=0) | NA |
| FC Gamma Receptor IIa R166H HH PD (n=0) | NA |
| FC Gamma Receptor IIa R166H HR CR (n=5) | 0.0 |
| FC Gamma Receptor IIa R166H HR PR (n=4) | 25.0 |
| FC Gamma Receptor IIa R166H HR SD (n=4) | 50.0 |
| FC Gamma Receptor IIa R166H HR PD (n=4) | 25.0 |
| FC Gamma Receptor IIa R166H RR CR (n=4) | 0.0 |
| FC Gamma Receptor IIa R166H RR PR (n=2) | 0.0 |
| FC Gamma Receptor IIa R166H RR SD (n=2) | 100.0 |
| FC Gamma Receptor IIa R166H RR PD (n=2) | 0.0 |
| FC Gamma Receptor IIb I232T II CR (n=4) | 0.0 |
| FC Gamma Receptor IIb I232T II PR (n=4) | 0.0 |
| FC Gamma Receptor IIb I232T II SD (n=4) | 75.0 |
| FC Gamma Receptor IIb I232T II PD (n=4) | 25.0 |
| FC Gamma Receptor IIb I232T IT CR (N=0) | NA |
| FC Gamma Receptor IIb I232T IT PR (n=0) | NA |
| FC Gamma Receptor IIb I232T IT SD (n=0) | NA |
| FC Gamma Receptor IIb I232T IT PD (n=0) | NA |
| FC Gamma Receptor IIb I232T TT CR (n=4) | 0.0 |
| FC Gamma Receptor IIb I232T TT PR (n=4) | 0.0 |
| FC Gamma Receptor IIb I232T TT SD (n=4) | 75.0 |
| FC Gamma Receptor IIb I232T TT PD (n=4) | 25.0 |
Best Overall response was defined according to RECIST. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or persistence of non-target lesions.
| percentage of participants | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) |
|---|---|
| Part I: CR (n=20) | 5.0 |
| Part I: PR (n=20) | 70.0 |
| Part I: SD (n=20) | 15.0 |
| Part I: PD (n=20) | 5.0 |
| Part I: Missing (n=20) | 5.0 |
| Part II: CR (n=9) | 0.0 |
| Part II: PR (n=9) | 11.1 |
| Part II: SD (n=9) | 66.7 |
| Part II: PD (n=9) | 22.2 |
| Part II: Missing (n=9) | 0.0 |
Collected over From the date of Screening until 4 weeks after the last visit of the participant. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | — | 9/33 (27.3%) | 33/33 (100%) |
| Event | All Participants |
|---|---|
| PyrexiaGeneral disorders | 2/33 |
| Chest painGeneral disorders | 1/33 |
| Medical device complicationGeneral disorders | 1/33 |
| CellulitisInfections and infestations | 1/33 |
| SepsisInfections and infestations | 1/33 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/33 |
| Cardiac failureCardiac disorders | 1/33 |
| Hip fractureInjury, poisoning and procedural complications | 1/33 |
| Back painMusculoskeletal and connective tissue disorders | 1/33 |
| MenorrhagiaReproductive system and breast disorders | 1/33 |
| Event | All Participants |
|---|---|
| Nail disorderSkin and subcutaneous tissue disorders | 23/33 |
| RashSkin and subcutaneous tissue disorders | 22/33 |
| FatigueGeneral disorders | 21/33 |
| DiarrhoeaGastrointestinal disorders | 20/33 |
| NauseaGastrointestinal disorders | 20/33 |
| AlopeciaSkin and subcutaneous tissue disorders | 16/33 |
| Peripheral sensory neuropathyNervous system disorders | 16/33 |
| HeadacheNervous system disorders | 15/33 |
| VomitingGastrointestinal disorders | 13/33 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/33 |
Intent-to-treat (ITT) population: All registered participants were included in the ITT population.
| Age, Continuous(years) | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks | No Group | Total |
|---|---|---|---|---|
| Mean | 55.5 ± 11.73 | 37.0 ± NA | 85.0 ± NA | 55.9 ± 12.91 |
| Sex: Female, Male(Participants) | Group A: Trastuzumab+Taxane /Capecitabine (6 Weeks) | Group B: Trastuzumab+Taxane/ Capecitabine <6 Weeks | No Group | Total |
|---|---|---|---|---|
| Female | 31 | 1 | 1 | 33 |
| Male | 0 | 0 | 0 | 0 |
Ran from Aug 2009 to primary completion in Feb 2013, 42 months.
Results were first posted in Oct 2015, 2 years 7 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 42 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Capecitabine · Trastuzumab